retatrutide peptide clinical trials efficacy (RETA) is one of the most promising investigational peptides in obesity research— Triple hormone receptor agonist retatrutide

The EY-Parthenon analysis projects usage to grow quickly in the coming 10 years to between 13% and 21% of US adults, a total market size of 30 million to 50 million people

Some supplement drops on the market are positioned as GLP-1s, though they are not regulated the same way an FDA-approved medication would be, meaning they are not held to the same standards for proving safety and efficacy, she explains

Cost, Insurance Coverage, and Access Public insurance coverage for GLP-1 obesity treatments is spotty in the United States

Glycemic control and insulin sensitivity For patients with type 2 diabetes or prediabetes, the HbA1c reduction from tirzepatide is substantial